These terms and conditions regulate the access and use of WebCim and all its subdomains or secondary domains including its contents and services, made available through the Internet Portal www.cim.cu WebCim may update at any time the conditions set forth in this document, as well as legal notices, guidelines and / or use regulations and, as the case may be, substitute, complete and / or modify the Terms and Conditions set out herein. It is recommended that you periodically consult the Terms and Conditions. By accessing WebCim you will be accepting the current terms and conditions.
You agree to use WebCim solely for legitimate purposes and in a way that does not infringe, restrict or inhibit the use and enjoyment of WebCim services, or to not use this page to perform activities contrary to law, morals, good Customs or established public order. You agree not to access, or attempt to access, any of the services using automated means, including scripts or web crawlers. Likewise, it undertakes not to engage in any activity that interferes or interrupts the services or the servers and networks connected to them.
The publishers will make all the efforts that are reasonable to try to guarantee the availability and accessibility of the page, as well as to its services, twenty-four hours a day during all the days of the year. However, sometimes, and, for example, due to causes such as the provision of new connections, address changes and / or the updating of maintenance operations that, in general, imply the suspension of access or use of the page , interruptions may occur for as long as it is necessary to undertake these tasks.
Here are some of the contents and services offered by WebCim:
News related to the Center of Molecular Immunology and the production process of medicines.
News of scientific, commercial and business events.
Send to the users expressly subscribed by email the monthly summary of the articles published in WebCim. WebCim will not disclose your email to third parties and will only use this information for the purposes stated above.
WebCim reserves the right to modify, at any time and without prior notice, the presentation and configuration of its contents and services. You expressly acknowledge and agree that at any time you can interrupt, deactivate and / or cancel any of the contents and / or services.
The copyright on the information of third parties that is published in WebCim belongs to their respective authors and their publication in WebCim is done without profit and with an informative purpose.
WebCim authorizes third parties to include in their websites access to the information published by WebCim using links to do so.
WebCim may contain links to websites that are controlled and maintained by third parties. WebCim makes every effort to make the published links available but is not responsible for the content or the availability of that information.
WebCim reserves the right to enable the comment mechanism for some of the articles or content published. The comments are the opinion of the user, it is not necessarily the position or opinion of WebCim. When they are inserted, they enter the queue of moderation and must be published in a short period of time. In any case, WebCim reserves the right to publish them, eliminating those that are off topic or use rude, violent, racist, offensive or contrary to the law.
In the cases that you detect irregularities, violations of these terms and conditions or want to clarify any doubt regarding our services you can write us to the email account firstname.lastname@example.org Editors of WebCim, January 17, 2019
¡Stay informed of our latest news!
CIMAvax EGF ® is a therapeutic vaccine registered in Cuba (developed by the Center of Molecular Immunology (CIM), for advanced lung cancer. This therapeutic vaccine has a health history in the indication: Advanced non-small cell lung cancer (NSCLC) stage IIIb and IV, after the first line of chemotherapy. It is in this condition and type of lung cancer that the greatest clinical benefit is obtained in terms of increased survival and improved quality of life, as well as a broad safety profile in treated patients. This vaccine is not recommended for other types of cancer, apart from NSCLC, the tumor must be primary pulmonary, because we have no evidence of efficacy to date. It is necessary to know the histology and tumor stage of the patient, since CIMAvax EGF ® is only registered for non-small cell lung cancer of advanced stage IIIb and IV cells (NSCLC), in other types of tumors we have no evidence of clinical efficacy .
Questions of Interest:
Position of CIM for CIMAvax EGF®:
The Center for Molecular Immunology (CIM) is the center where it develops, produces and markets this medicine among other biotechnological products. This institution does not offer treatments to patients directly, nor does it inform about the price of the products they produce.
Foreign patients should contact the Cuban Medical Services who will evaluate each case if they are susceptible to treatment with these vaccines and receive it within a comprehensive program of patient care with commercial value.
You can contact them at these addresses:
At the International Clinic La Pradera:
Phones (537) 2737467 ext. 403
If you want a treatment outside of Cuba:
Laboratorio Libra Paraguay S.A
Dirección: Pedro Ciancio 1443 entre Santiago y San Cosme B Jara Asunción Persona de Contacto: Sr. Pablo Moreira Gerente Comercial
Correo electrónico: email@example.com
Teléfono: (595-21) 228 370
Móvil: (595) 986 679300
Sr. Alejandro Castaño.
Tel: + 57-4-334 40 33
Móvil: +57 - 311 301 8257
Cra.46 # 19 sur 117
Medellín, Colombia, América del Sur
Laboratorio Elea Phoenix S.A.
Sanabria 2353 (C1417AZE), Ciudad Autónoma de Buenos Aires, Argentina
Tel. (5411) 4379 4300 (int. 1266)
Director médico Dr. Matias DEPRATI
050033, Almaty, Khodzhanova street, 13 house, 69
CEO. Alina Ilimbayeva
+7 701 715 6000
Kraljice Natalije 46
Tel: +381 11 36 28 433
CEO. Mr. Zoran Vujovic.
Si necesita cualquier información adicional, no dude en contactarnos.